Why the study?
Does transplacental digoxin therapy improve fetal supraventricular tachycardia in a twin pregnancy?
Does transplacental digoxin therapy improve fetal supraventricular tachycardia in a twin pregnancy?
Transplacental digoxin therapy can successfully and safely treat fetal supraventricular tachycardia with hydrops in a twin pregnancy.
May support transplacental digoxin for fetal SVT in twins; hypothesis-generating and should not change practice.
A case of a twin pregnancy in which one fetus developed hydrops secondary to supraventricular tachycardia was detected at 21 weeks' gestation. Transplacental digoxin therapy successfully converted the supraventricular tachycardia to a normal sinus rhythm without evidence of maternal or fetal side-effects. The pregnancy proceeded to term and elective cesarean section was carried out at 37 weeks' gestation.
No takes yet. Share an insight, caveat, or question.
Tanawattanacharoen et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: